Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Adjuvant KEYTRUDA® (pembrolizumab) in early-stage renal cell carcinoma (RCC)

RCC Pre-Operative Considerations & Post-Operative MDT Decision Aid

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYNOTE-564 slide deck

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Adjuvant RCC patient identification guide

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

For more information about adjuvant KEYTRUDA in early-stage RCC:

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.¹

Please refer to the Summary of Product Characteristics and risk minimisation materials before making prescribing decisions.

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website